Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IT&E International Group and VaxGen have agreed to further expand their long-term, multi-million dollar agreement in developing a vaccine against anthrax for the US government.
Subscribe to our email newsletter
IT&E has been awarded additional long-term contracts to continue its relationship with VaxGen, to provide additional services to support the production of 75 million doses of VaxGen’s anthrax vaccine for the US government’s strategic national stockpile.
Funded by the US Department of Health and Human Services, this project is part of the US government’s Project BioShield that has called for $5.6 billion in federal funds for the procurement of bio-terrorism countermeasures such as vaccines for smallpox and anthrax and to speed up their availability.
In 2003, IT&E signed an agreement to assist VaxGen in completing its validation efforts related to the development and production of a modern anthrax vaccine for the National Institute of Allergy and Infectious Diseases (NIAID).
Under the terms of the newly expanded agreement, IT&E will now provide services to VaxGen in support of the production of its anthrax vaccine for the strategic national stockpile. These services encompass providing support in the areas of validation and compliance in VaxGen’s manufacturing facilities, equipment, utilities and analytical systems.